blocker losartan is used in patients with renal and cardiovascular diseases. [ 18 F]fluoropyridine-losartan has shown favorable binding profile for quantitative renal PET imaging of AT 1 R with selective binding in rats and pigs, low interference of radiometabolites and appropriate dosimetry for clinical translation. A new approach was developed to produce [ 18 F]fluoropyridine-losartan in very high molar activity. Automated radiosynthesis was performed in a three-step, two-pot, and two-HPLCpurification procedure within 2 h. Pure [ 18 F]FPyKYNE was obtained by radiofluorination of NO 2 PyKYNE and silica-gel-HPLC purification (40 ± 9%), preventing the formation of nitropyridine-losartan in the second step. Conjugation with trityl-losartan azide via click chemistry, followed by acid hydrolysis, C18-HPLC purification and reformulation provided [ 18 F]fluoropyridine-losartan in 11 ± 2% (decay-corrected from [ 18 F]fluoride, EOB). Using tris [(1-(3-hydroxypropyl)-1H-1,2,3-triazol-4-yl)methyl]-amine (THPTA) as a Cu(I)stabilizing agent for coupling [ 18 F]FPyKYNE to the unprotected losartan azide afforded [ 18 F]fluoropyridine-losartan in similar yields (11 ± 3%, decaycorrected from [ 18 F]fluoride, EOB). Reverse-phase HPLC was optimized by reducing the pH of the mobile phase to achieve complete purification and high
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.